2026-11-09

China A-share innovative-drug stocks rose intraday after choppy trading; Laimei Pharmaceutical jumped more than 15%, with Zhaoyan New Drug, Medicilon, Chengdu Xiandao, RemeGen and Nearshore Protein among the top gainers.

China A-share innovative-drug stocks rose intraday after choppy trading; Laimei Pharmaceutical jumped more than 15%, with Zhaoyan New Drug, Medicilon, Chengdu Xiandao, RemeGen and Nearshore Protein among the top gainers.

2026-11-09

A股創新藥概念盤中震盪走高，萊美藥業漲超15%，昭衍新藥、美迪西、成都先導、榮昌生物、近岸蛋白漲幅靠前。

A股創新藥概念盤中震盪走高，萊美藥業漲超15%，昭衍新藥、美迪西、成都先導、榮昌生物、近岸蛋白漲幅靠前。

2026-11-09

【期貨熱點追蹤】生豬供強需弱未改、均重上升累庫存，超跌修復遇上弱現實壓制，生豬主力合約能否扭轉下跌趨勢？

【期貨熱點追蹤】生豬供強需弱未改、均重上升累庫存，超跌修復遇上弱現實壓制，生豬主力合約能否扭轉下跌趨勢？

2026-11-09

Hong Kong biotech stocks were firmer in early trade. Zai Lab (09688.HK) jumped over 12%, Akeso (09926.HK) rose ~7%, Ascentage Pharma (06855.HK) gained ~5%, Kangnuoya (02162.HK) added ~4%, BeiGene (06160.HK) was up just over 3%, and Rongchang Bio (09995.HK) rose ~3%.

Hong Kong biotech stocks were firmer in early trade. Zai Lab (09688.HK) jumped over 12%, Akeso (09926.HK) rose ~7%, Ascentage Pharma (06855.HK) gained ~5%, Kangnuoya (02162.HK) added ~4%, BeiGene (06160.HK) was up just over 3%, and Rongchang Bio (09995.HK) rose ~3%.

2026-11-09

港股生物技術股盤初上揚，再鼎醫藥(09688.HK)大漲超12%，康方生物(09926.HK)漲近7%，亞盛醫藥(06855.HK)漲近5%，康諾亞(02162.HK)漲近4%，百濟神州(06160.HK)漲超3%，榮昌生物(09995.HK)漲近3%。

港股生物技術股盤初上揚，再鼎醫藥(09688.HK)大漲超12%，康方生物(09926.HK)漲近7%，亞盛醫藥(06855.HK)漲近5%，康諾亞(02162.HK)漲近4%，百濟神州(06160.HK)漲超3%，榮昌生物(09995.HK)漲近3%。

2026-11-09

President Trump endorsed a bipartisan bill to speed federal permitting for major energy and infrastructure projects ahead of a Senate procedural vote Monday, urging senators to support legislation he said would codify an "America First" energy agenda and accelerate pipelines, mines and power-plant construction. Supporters say the measure would shorten approvals critical to grid modernization, AI data-center builds and some clean-energy projects; it has backing from oil companies and renewable de

President Trump endorsed a bipartisan bill to speed federal permitting for major energy and infrastructure projects ahead of a Senate procedural vote Monday, urging senators to support legislation he said would codify an "America First" energy agenda and accelerate pipelines, mines and power-plant construction. Supporters say the measure would shorten approvals critical to grid modernization, AI data-center builds and some clean-energy projects; it has backing from oil companies and renewable developers. Passage faces obstacles: Congress has about two months left in the session, House Democratic leader Jeffries opposes the current text for lack of Democratic input, and progressive Democrats prefer to press for a stronger deal next year.